AJPT Cover
Frequency: Continuous
ISSN: 1557-4962 (Print)
ISSN: 1557-4970 (Online)
Research Article Open Access

RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW

Anjo Sunny1, M. Arif Khan1, Darpelly Mahesh1, Nikhil Singh Chauhan1, Ritu Mishra1, Namindla Presila1 and Asa Samuel1
  • 1 National Institute of Pharmaceutical Education and Research, India

Abstract

The purpose of this review is to give the readers an insight about the risks and benefits of ’quinapril’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, an attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day clinical practice.

American Journal of Pharmacology and Toxicology
Volume 9 No. 1, 2014, 68-74

DOI: https://doi.org/10.3844/ajptsp.2014.68.74

Submitted On: 28 December 2013 Published On: 12 February 2014

How to Cite: Sunny, A., Khan, M. A., Mahesh, D., Chauhan, N. S., Mishra, R., Presila, N. & Samuel, A. (2014). RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW. American Journal of Pharmacology and Toxicology, 9(1), 68-74. https://doi.org/10.3844/ajptsp.2014.68.74

Open AccessCopyright: © 2014 Anjo Sunny, M. Arif Khan, Darpelly Mahesh, Nikhil Singh Chauhan, Ritu Mishra, Namindla Presila and Asa Samuel. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

  • 4,224 Views
  • 3,865 Downloads
  • 0 Citations

Download

Keywords

  • Quinapril
  • Benefit
  • Risk
  • Hypertension